Cite
MLA Citation
Neil Berinstein et al.. “356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A217–A218. http://access.bl.uk/ark:/81055/vdc_100144718278.0x000005